Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer

Targeting BRAF V600E mutation has been proven effective in the treatment of several types of cancer. In endometrial adenocarcinoma, the BRAF V600E mutation has been rarely reported. Whether targeting BRAF oncogene may represent a plausible therapeutic strategy for the rare patients with BRAF-mutated...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Experimental hematology & oncology 2017-01, Vol.6 (1), p.1, Article 1
Hauptverfasser:	Moschetta, Michele, Mak, Gabriel, Hauser, Joana, Davies, Catriona, Uccello, Mario, Arkenau, Hendrik-Tobias
Format:	Artikel
Sprache:	eng
Schlagworte:	Care and treatment Case Report Dabrafenib Development and progression Endometrial cancer Gene mutation Genetic aspects Health aspects Microsatellites (Genetics) Patient outcomes Trametinib
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!